Niagen Bioscience Inc
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Robert N. Fried
- Full Time Employees
- 104
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 10900 Wilshire Blvd, Suite 600 Los Angeles CA United States of America 90024
- IPO Date
- Jun 24, 2015
- CIK
- 0001386570
- Website
- niagenbioscience.com
- Similar Companies
- Business
- Niagen Bioscience Inc (Ticker: NAGE) develops and commercializes innovative bioscience products focused on cellular health and energy metabolism, primarily through nicotinamide riboside (NR) branded as Niagen, a clinically validated precursor to NAD+ that supports mitochondrial function and healthy aging. The company offers Niagen in various formulations, including bulk ingredients for dietary supplements, branded consumer products such as capsules and powders, and custom formulations for sports nutrition and longevity markets; it also provides research-grade Niagen for clinical studies and contract manufacturing services for NAD+-boosting nutraceuticals. Headquartered in Reno, Nevada, Niagen Bioscience was founded in 2013 as part of the ChromaDex ecosystem before spinning out as an independent entity, with operations spanning North America, Europe, and Asia-Pacific targeting supplement manufacturers, healthcare professionals, and direct-to-consumer channels in the nutraceutical and wellness industries. In late 2024, the company completed a significant uplisting to NASDAQ under ticker NAGE following a reverse merger, enhancing its capital access for global expansion; it announced a strategic partnership with a leading Asian distributor to accelerate Niagen adoption in the high-growth longevity market and launched Niagen Pro, a professional-grade line for practitioners in 2025. Niagen Bioscience continues to invest in R&D for next-generation NAD+ precursors amid rising demand for anti-aging interventions, with no major subsidiaries but key alliances with contract manufacturers worldwide.
Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference
Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science
Niagen Bioscience Announces Participation in Upcoming Investor Conferences
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Top Estimates
Niagen Bioscience, Inc. (NAGE) Q1 2026 Earnings Call Transcript
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Niagen Bioscience Launches Niagen Plus Telehealth Platform, Unveiling At-Home Injection Kit Offering
Niagen Bioscience Adds Olympia Pharmaceuticals to 503B Compounding Partner Network for Niagen Plus™
Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026
Niagen Bioscience: How Its Shift To Telehealth Makes It A Strong Buy
Niagen: High-Quality Growth At A Fair Price
Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
JPMorgan Chase & Co. Makes New $3.68 Million Investment in Niagen Bioscience, Inc. $NAGE
Niagen Bioscience Announces First Cruise Ship Clinic Partnership with OneSpaWorld, Bringing the NAD-Boosting Benefits of Niagen IV to the High Seas
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Niagen Bioscience to Present at the 38th Annual ROTH Conference
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
Niagen Bioscience Launches Niagen® Skincare Innovation Lab and Debuts Dermatologist-Tested Niagen NanoCloud™, From Tru Niagen Powered by Patented Niagen®
Niagen Bioscience Doubles Annual Profit, CEO Signals Acquisition Hunt And GLP-1-Style Expansion— Stock Jumps After-Hours (UPDATED)
Niagen Bioscience, Inc. (NAGE) Q4 2025 Earnings Call Transcript